Niklas Loman

14.3k total citations · 3 hit papers
52 papers, 5.8k citations indexed

About

Niklas Loman is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Niklas Loman has authored 52 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Genetics, 21 papers in Molecular Biology and 15 papers in Oncology. Recurrent topics in Niklas Loman's work include BRCA gene mutations in cancer (37 papers), DNA Repair Mechanisms (13 papers) and Ovarian cancer diagnosis and treatment (12 papers). Niklas Loman is often cited by papers focused on BRCA gene mutations in cancer (37 papers), DNA Repair Mechanisms (13 papers) and Ovarian cancer diagnosis and treatment (12 papers). Niklas Loman collaborates with scholars based in Sweden, United States and United Kingdom. Niklas Loman's co-authors include Michael Friedländer, M. William Audeh, Åke Borg, Håkan Olsson, Andrew Tutt, Clare L. Scott, Karen H. Lu, Ana Oaknin, Katherine M. Bell‐McGuinn and Richard T. Penson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Communications.

In The Last Decade

Niklas Loman

51 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

2010 1.7k citations Niklas Loman et al. profile →
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation

2014 1.2k citations Bella Kaufman, Judith Balmañà et al. profile →
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression

2017 408 citations Asís Palazón, Petros A. Tyrakis et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Niklas Loman Sweden	27	3.4k	2.6k	2.2k	1.7k	999	52	5.8k
Judith Balmañà Spain	36	3.9k 1.2×	2.6k 1.0×	2.4k 1.1×	1.6k 0.9×	996 1.0×	179	6.5k
Rinat Yerushalmi Israel	27	4.4k 1.3×	2.2k 0.9×	1.2k 0.5×	2.3k 1.3×	460 0.5×	119	6.7k
M. William Audeh United States	16	4.1k 1.2×	2.7k 1.0×	1.6k 0.7×	1.2k 0.7×	998 1.0×	35	5.2k
Kirsten M. Timms United States	27	2.6k 0.7×	2.2k 0.8×	1.5k 0.7×	1.2k 0.7×	681 0.7×	96	4.6k
Nuala McCabe United Kingdom	19	5.0k 1.5×	5.1k 1.9×	1.3k 0.6×	1.2k 0.7×	672 0.7×	43	7.2k
Heli Nevanlinna Finland	43	1.7k 0.5×	3.1k 1.2×	2.3k 1.0×	1.5k 0.9×	260 0.3×	124	5.2k
John I. Risinger United States	41	1.6k 0.5×	3.2k 1.2×	850 0.4×	1.7k 1.0×	915 0.9×	94	5.8k
Constance T. Albarracin United States	43	1.7k 0.5×	1.8k 0.7×	894 0.4×	2.1k 1.2×	320 0.3×	122	5.2k
Rita K. Schmutzler Germany	22	2.7k 0.8×	2.5k 1.0×	1.3k 0.6×	917 0.5×	488 0.5×	49	4.1k
David S. Boss Netherlands	14	3.1k 0.9×	2.5k 1.0×	939 0.4×	778 0.5×	713 0.7×	24	4.4k

Countries citing papers authored by Niklas Loman

Since Specialization

Citations

This map shows the geographic impact of Niklas Loman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niklas Loman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niklas Loman more than expected).

Fields of papers citing papers by Niklas Loman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Niklas Loman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niklas Loman. The network helps show where Niklas Loman may publish in the future.

Co-authorship network of co-authors of Niklas Loman

This figure shows the co-authorship network connecting the top 25 collaborators of Niklas Loman. A scholar is included among the top collaborators of Niklas Loman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Niklas Loman. Niklas Loman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Augustinsson, Annelie, Niklas Loman, & Hans Ehrencrona. (2024). Retrospective genetic testing (Traceback) in women with early-onset breast cancer after revised national guidelines: a clinical implementation study. Breast Cancer Research and Treatment. 205(3). 599–607.

Ólafsdóttir, Elínborg J., Åke Borg, Maj‐Britt Jensen, et al.. (2020). Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status. British Journal of Cancer. 123(11). 1608–1615. 8 indexed citations

Singer, Christian F., Judith Balmañà, Nicole Bürki, et al.. (2018). Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer—an European consensus statement and expert recommendations. European Journal of Cancer. 106. 54–60. 25 indexed citations

Nilsson, Martin, et al.. (2018). Written pretest information and germline BRCA1/2 pathogenic variant testing in unselected breast cancer patients: predictors of testing uptake. Genetics in Medicine. 21(1). 89–96. 4 indexed citations

Palazón, Asís, Petros A. Tyrakis, David Macías, et al.. (2017). An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. Cancer Cell. 32(5). 669–683.e5. 408 indexed citations breakdown →

Nilsson, Martin, Christof Winter, Ulf Kristoffersson, et al.. (2017). Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer. Familial Cancer. 16(2). 187–193. 17 indexed citations

Nilsson, Martin, Therese Törngren, Karin Henriksson, et al.. (2017). BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer. Breast Cancer Research and Treatment. 168(1). 117–126. 14 indexed citations

Winter, Christof, Martin Nilsson, Eric Olsson, et al.. (2016). Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Annals of Oncology. 27(8). 1532–1538. 105 indexed citations

Kimbung, Siker, Ida Johansson, Anna Danielsson, et al.. (2015). Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer. Clinical Cancer Research. 22(1). 146–157. 36 indexed citations

10.

Nilsson, Martin, Linda Hartman, Ingrid Idvall, et al.. (2014). Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status. Breast Cancer Research and Treatment. 144(1). 133–142. 21 indexed citations

11.

Nilsson, Martin, Linda Hartman, Ulf Kristoffersson, et al.. (2014). High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer. Breast Cancer Research and Treatment. 147(3). 571–578. 39 indexed citations

12.

Kimbung, Siker, Ida Johansson, Kristina Aaltonen, et al.. (2012). Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition. Cancer Letters. 319(2). 232–241. 37 indexed citations

13.

Jernström, Helena, Niklas Loman, Oskar T. Johannsson, Åke Borg, & Håkan Olsson. (2005). Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. European Journal of Cancer. 41(15). 2312–2320. 53 indexed citations

14.

Malander, Susanne, Mona Ridderheim, Anna Måsbäck, et al.. (2003). One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations. European Journal of Cancer. 40(3). 422–428. 71 indexed citations

15.

Koul, Anjila, Niklas Loman, Susanne Malander, Åke Borg, & Mona Ridderheim. (2001). Two BRCA1-Positive Epithelial Ovarian Tumors with Metastases to the Central Nervous System: A Case Report. Gynecologic Oncology. 80(3). 399–402. 11 indexed citations

16.

Loman, Niklas, Óskar Þór Jóhannsson, Pär‐Ola Bendahl, et al.. (2000). Prognosis and clinical presentation of BRCA2-associated breast cancer. European Journal of Cancer. 36(11). 1365–1373. 40 indexed citations

17.

Malander, Susanne, Niklas Loman, Tanja Pejović, et al.. (2000). BRCA1 and BRCA2 mutations in ovarian cancer: Covariation with specific cytogenetic features. International Journal of Gynecological Cancer. 10(4). 289–295. 10 indexed citations

18.

Jernström, Helena, Óskar Þór Jóhannsson, Niklas Loman, Åke Borg, & Håkan Olsson. (1999). Reproductive factors in hereditary breast cancer. Breast Cancer Research and Treatment. 58(3). 293–299. 14 indexed citations

19.

Jóhannsson, Óskar Þór, Niklas Loman, Henrik Møller, et al.. (1999). Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. European Journal of Cancer. 35(8). 1248–1257. 89 indexed citations

20.

Elston, Robert C., et al.. (1998). Analysis of Swedish male breast cancer family data: A simple way to incorporate a common sibling effect. Genetic Epidemiology. 15(2). 201–212. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact